<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001799.pub2" GROUP_ID="UPPERGI" ID="634199101816372779" MERGED_FROM="" MODIFIED="2012-02-13 15:51:04 +0100" MODIFIED_BY="Karin Dearness" NOTES="&lt;p&gt;Short title (no longer in use): Preoperative Radiotherapy in Esophageal Cancer&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-02-11 07:13:44 +0000" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="32" REVMAN_SUB_VERSION="5.0.23" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="15.0">
<COVER_SHEET MODIFIED="2012-02-13 15:51:04 +0100" MODIFIED_BY="Karin Dearness">
<TITLE>Preoperative radiotherapy for esophageal carcinoma</TITLE>
<CONTACT MODIFIED="2012-02-13 15:51:04 +0100" MODIFIED_BY="Karin Dearness"><PERSON ID="8931" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jayne</FIRST_NAME><LAST_NAME>Tierney</LAST_NAME><POSITION>Head, Meta-analysis Group</POSITION><EMAIL_1>jt@ctu.mrc.ac.uk</EMAIL_1><ADDRESS><ORGANISATION>MRC Clinical Trials Unit</ORGANISATION><ADDRESS_1>Aviation House</ADDRESS_1><ADDRESS_2>125 Kingsway</ADDRESS_2><CITY>London</CITY><ZIP>WC2B 6NH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+ 44 20 7670  4724</PHONE_1><FAX_1>+ 44 20 7670 4949</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-02-13 15:51:04 +0100" MODIFIED_BY="Karin Dearness"><PERSON ID="19318" ROLE="AUTHOR"><FIRST_NAME>Sydney</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Arnott</LAST_NAME><ADDRESS><ORGANISATION>St Bartholomew's Hospital</ORGANISATION><ADDRESS_2>West Smithfield</ADDRESS_2><CITY>London</CITY><ZIP>EC1A 7BE</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 7601 8334</PHONE_1><PHONE_2>+44 20 7601 8364</PHONE_2></ADDRESS></PERSON><PERSON ID="63D8C07082E26AA200991D566903B8F0" ROLE="AUTHOR"><FIRST_NAME>W</FIRST_NAME><LAST_NAME>Duncan</LAST_NAME><POSITION>c/o Dr Jayne Tierney</POSITION><ADDRESS><DEPARTMENT>Meta-analysis Group</DEPARTMENT><ORGANISATION>MRC Clinical Trials Unit</ORGANISATION><ADDRESS_1>222 Euston Road</ADDRESS_1><CITY>London</CITY><ZIP>CB2 2BW</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="E1BE5C6482E26AA201DAB7D85A9A4A39" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>M</FIRST_NAME><LAST_NAME>Gignoux</LAST_NAME><ADDRESS><DEPARTMENT>Service de Chirurgie Digestive</DEPARTMENT><ORGANISATION>Centre Hospitalier Universitaire</ORGANISATION><ADDRESS_1>Niveau 7</ADDRESS_1><ADDRESS_2>Avenue de Cote de Nacre</ADDRESS_2><CITY>Caen</CITY><ZIP>14033 cedex</ZIP><COUNTRY CODE="FR">France</COUNTRY><PHONE_1>+332 3106 4470</PHONE_1><FAX_1>+332 3106 4468</FAX_1></ADDRESS></PERSON><PERSON ID="9388" ROLE="AUTHOR"><PREFIX>Dr.</PREFIX><FIRST_NAME>David</FIRST_NAME><LAST_NAME>Girling</LAST_NAME><POSITION>Senior Scientist</POSITION><EMAIL_1>david.girling@ctu.mrc.ac.uk</EMAIL_1><URL>http://www.ctu.mrc.ac.uk</URL><ADDRESS><DEPARTMENT>Cancer Division</DEPARTMENT><ORGANISATION>MRC Clinical Trials Unit</ORGANISATION><ADDRESS_1>222 Euston Road</ADDRESS_1><ADDRESS_2>5 Shaftesbury Road</ADDRESS_2><CITY>London</CITY><ZIP>NW1 2DA</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 7670 4734 ext: 239</PHONE_1><FAX_1>+44 20 7670 4818</FAX_1></ADDRESS></PERSON><PERSON ID="6D43927A82E26AA20075541C7E9B8D12" ROLE="AUTHOR"><FIRST_NAME>H</FIRST_NAME><LAST_NAME>Hansen</LAST_NAME><POSITION>c/o Jayne Tierney</POSITION><ADDRESS><DEPARTMENT>Meta-analysis Group</DEPARTMENT><ORGANISATION>MRC Clinical Trials Unit</ORGANISATION><ADDRESS_1>222 Euston Road</ADDRESS_1><CITY>London</CITY><ZIP>NW1 2DA</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="DA42A35682E26AA2001A75537E8B88E7" ROLE="AUTHOR"><FIRST_NAME>Bernard</FIRST_NAME><LAST_NAME>Launois</LAST_NAME><EMAIL_1>bernard.launois@univ-rennes1.fr</EMAIL_1><ADDRESS><DEPARTMENT>Department of Digestive Surgery</DEPARTMENT><ORGANISATION>Hospital Pontchaillou</ORGANISATION><ADDRESS_1>Rue Henri Le Guilloux</ADDRESS_1><CITY>Rennes</CITY><ZIP>35033 RENNES</ZIP><COUNTRY CODE="FR">France</COUNTRY><PHONE_1>+3 32 99 28 42 21</PHONE_1><FAX_1>+3 32 99 22 41 29</FAX_1></ADDRESS></PERSON><PERSON ID="DA4E287F82E26AA2001A75535365B797" ROLE="AUTHOR"><FIRST_NAME>K</FIRST_NAME><LAST_NAME>Nygaard</LAST_NAME><ADDRESS><ORGANISATION>Kirurgisk Afdelling</ORGANISATION><ADDRESS_1>Aker Sygenhus</ADDRESS_1><CITY>Oslo</CITY><ZIP>N-0514</ZIP><COUNTRY CODE="NO">Norway</COUNTRY><PHONE_1>+47 74 22 22 56 48</PHONE_1></ADDRESS></PERSON><PERSON ID="DA50035982E26AA2001A7553C87D8867" ROLE="AUTHOR"><FIRST_NAME>Mahesh</FIRST_NAME><MIDDLE_INITIALS>KB</MIDDLE_INITIALS><LAST_NAME>Parmar</LAST_NAME><POSITION>Head</POSITION><EMAIL_1>max.parmar@ctu.mrc.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Cancer Division</DEPARTMENT><ORGANISATION>MRC Clinical Trials Unit</ORGANISATION><ADDRESS_1>222 Euston Road</ADDRESS_1><CITY>London</CITY><ZIP>NW1 2DA</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 7670 4729</PHONE_1><FAX_1>+44 20 7670 4818</FAX_1></ADDRESS></PERSON><PERSON ID="DA53D43782E26AA2001A7553D26F12B7" ROLE="AUTHOR"><FIRST_NAME>A</FIRST_NAME><LAST_NAME>Rousell</LAST_NAME><ADDRESS><DEPARTMENT>Centre Regional Francois</DEPARTMENT><ORGANISATION>Ballesse</ORGANISATION><CITY>Caen</CITY><COUNTRY CODE="FR">France</COUNTRY></ADDRESS></PERSON><PERSON ID="DA584EF282E26AA2001A755342896854" ROLE="AUTHOR"><FIRST_NAME>G</FIRST_NAME><LAST_NAME>Spiliopoulos</LAST_NAME><ADDRESS><DEPARTMENT>Centre De Chirurgie Digestive Et Unite of Transplantation</DEPARTMENT><ORGANISATION>Hospitalier Regional et Universitaire De Rennes</ORGANISATION><ADDRESS_1>Pontchailier 35033</ADDRESS_1><CITY>Rennes Cedfx</CITY><COUNTRY CODE="FR">France</COUNTRY><PHONE_1>+332 99 28 42 21</PHONE_1><FAX_1>+332 99 27 41 29</FAX_1></ADDRESS></PERSON><PERSON ID="8177" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Lesley</FIRST_NAME><LAST_NAME>Stewart</LAST_NAME><POSITION>Director</POSITION><EMAIL_1>lesley.stewart@york.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Centre for Reviews and Dissemination</DEPARTMENT><ORGANISATION>University of York</ORGANISATION><CITY>York</CITY><ZIP>YO10 5DD</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 (0)1904 321093</PHONE_1><FAX_1>+44 (0)1904 321041</FAX_1></ADDRESS></PERSON><PERSON ID="8931" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jayne</FIRST_NAME><LAST_NAME>Tierney</LAST_NAME><POSITION>Head, Meta-analysis Group</POSITION><EMAIL_1>jt@ctu.mrc.ac.uk</EMAIL_1><ADDRESS><ORGANISATION>MRC Clinical Trials Unit</ORGANISATION><ADDRESS_1>Aviation House</ADDRESS_1><ADDRESS_2>125 Kingsway</ADDRESS_2><CITY>London</CITY><ZIP>WC2B 6NH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+ 44 20 7670  4724</PHONE_1><FAX_1>+ 44 20 7670 4949</FAX_1></ADDRESS></PERSON><PERSON ID="6D455A6982E26AA20075541C6EF136E9" ROLE="AUTHOR"><FIRST_NAME>M</FIRST_NAME><LAST_NAME>Wang</LAST_NAME><POSITION>c/o Jayne Tierney</POSITION><ADDRESS><DEPARTMENT>Meta-analysis Group</DEPARTMENT><ORGANISATION>MRC Clinical Trials Unit</ORGANISATION><ADDRESS_1>222 Euston Road</ADDRESS_1><CITY>London</CITY><ZIP>NW1 2DA</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="DA5325D782E26AA2001A7553E0C0FF6C" ROLE="AUTHOR"><FIRST_NAME>Z</FIRST_NAME><LAST_NAME>Rhugang</LAST_NAME><ADDRESS><DEPARTMENT>Department of Radiation Oncology</DEPARTMENT><ORGANISATION>Cancer Hospital</ORGANISATION><ADDRESS_1>P O Box 2258</ADDRESS_1><CITY>Beijing</CITY><ZIP>100021</ZIP><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 10 781331</PHONE_1><FAX_1>+86 10 7713359</FAX_1></ADDRESS></PERSON><GROUP ID="8D55A98682E26AA201830EC722FADCEE"><GROUP_NAME>Oeosphageal Cancer Collaborative Group</GROUP_NAME><ADDRESS><ORGANISATION/><CITY>London</CITY><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></GROUP></CREATORS>
<DATES MODIFIED="2009-03-31 18:35:34 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="31" MONTH="3" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="9" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2005"/>
</DATES>
<WHATS_NEW MODIFIED="2012-02-13 15:51:04 +0100" MODIFIED_BY="Karin Dearness"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-02-13 15:51:04 +0100" MODIFIED_BY="Karin Dearness"><DATE DAY="13" MONTH="2" YEAR="2012"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2009-04-28 14:26:57 +0100" MODIFIED_BY="Cathy Bennett">
<DATE DAY="31" MONTH="3" YEAR="2009"/>
<DESCRIPTION>
<P>Searches, tables and figures last updated March 2009. Declared stable and no future updates planned.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2012-02-13 15:51:04 +0100" MODIFIED_BY="Karin Dearness"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-02-13 15:51:04 +0100" MODIFIED_BY="Karin Dearness"><DATE DAY="5" MONTH="10" YEAR="2010"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-04-28 14:05:19 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="30" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Medical Research Council</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-02-11 06:50:22 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2009-04-28 14:50:23 +0100" MODIFIED_BY="Cathy Bennett">
<TITLE MODIFIED="2009-04-28 14:49:38 +0100" MODIFIED_BY="Cathy Bennett">Preoperative radiotherapy for esophageal carcinoma (cancer of the gullet)</TITLE>
<SUMMARY_BODY MODIFIED="2009-04-28 14:50:23 +0100" MODIFIED_BY="Cathy Bennett">
<P>If the tumour has not spread, surgery is usually the standard treatment for cancer of the esophagus (the tube between the throat and stomach). Surgery to remove the cancer can help people to live longer, but the prognosis is still very poor. Trials have tried using radiotherapy (x-ray treatment) before the operation. It was hoped that this would make the tumour smaller, less likely to spread and let people live longer. However, the review of trials found no clear evidence that radiotherapy before surgery for cancer of the esophagus increases a patient's chances of survival.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-04-28 14:23:10 +0100" MODIFIED_BY="Cathy Bennett">
<ABS_BACKGROUND>
<P>The existing randomized evidence has failed to conclusively demonstrate the benefit or otherwise of preoperative radiotherapy in treating patients with potentially resectable esophageal carcinoma.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>This meta-analysis aimed to assess whether there is benefit from adding radiotherapy prior to surgery and whether or not any pre-defined patient subgroups benefit more or less from preoperative radiotherapy</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-04-28 14:23:10 +0100" MODIFIED_BY="Cathy Bennett">
<P>MEDLINE and CancerLit searches were supplemented by information from trial registers and by hand searching relevant meeting proceedings and by discussion with relevant trialists, organisations and industry. The search strategy was run again in MEDLINE, EMBASE and the Cochrane Library on 30th April 2000; in MEDLINE, EMBASE, CancerLit and The Cochrane Library on August 2002 and August 2003; on MEDLINE, EMBASE and the Cochrane Library, on July 2004 and 2005, June 2006 and September 2008. No new relevant trials were identified on any of these occasions.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Trials were eligible for inclusion in this meta-analysis provided they randomized patients with potentially resectable carcinoma of the esophagus (of any histological type) to receive radiotherapy or no radiotherapy prior to surgery. Trials must have used a randomization method which precluded prior knowledge of treatment assignment and completed accrual by December 1993, to ensure sufficient follow-up by the time of the first analysis (September 1995).</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>A quantitative meta-analysis using updated data from individual patients from all properly randomized trials (published or unpublished) comprising 1147 patients (971 deaths) from five randomized trials. This approach was used to assess whether preoperative radiotherapy improves overall survival and whether it is differentially effective in patients defined by age, sex and tumour location.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>With a median follow-up of 9 years, in a group patients with mostly squamous carcinomas, the hazard ratio (HR) of 0.89 (95% CI 0.78-1.01) suggests an overall reduction in the risk of death of 11% and an absolute survival benefit of 3% at 2 years and 4% at 5 years. This result is not conventionally statistically significant (p=0.062). No clear differences in the size of the effect by sex, age or tumor location were apparent.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Based on existing trials, there was no clear evidence that preoperative radiotherapy improves the survival of patients with potentially resectable esophageal cancer. These results indicate that if such preoperative radiotherapy regimens do improve survival, then the effect is likely to be modest with an absolute improvement in survival of around 3 to 4%. Trials or a meta-analysis of around 2000 patients (90% power, 5% significance level) would be needed to reliably detect such an improvement (from 15 to 20%).</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-02-11 06:50:22 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2009-03-17 12:29:34 +0000" MODIFIED_BY="[Empty name]">
<P>Most patients with esophageal carcinoma have loco-regional or more advanced disease at diagnosis, with overall 5-year survival of approximately 10% (<LINK REF="REF-Boring-1993" TYPE="REFERENCE">Boring 1993</LINK>). Surgical resection is standard therapy for patients with localized tumours (<LINK REF="REF-DeMeester-1988" TYPE="REFERENCE">DeMeester 1988</LINK>) and while their prognosis is better, it is still poor (15%). One reason being that loco-regional recurrences are frequent even after intended curative resection. Following the results of numerous uncontrolled historical studies (reviewed in <LINK REF="STD-Gignoux-1988" TYPE="STUDY">Gignoux 1988</LINK>) there has been interest in the use of preoperative radiotherapy as a possible means of reducing local spread, thereby, improving survival. By downstaging the tumor, it may also increase resectability and perhaps alleviate symptoms.</P>
<P>Five prospective randomized controlled trials have investigated the effects of preoperative radiotherapy. Although pathological responses were reported in four of these trials (<LINK REF="STD-Arnott-1992" TYPE="STUDY">Arnott 1992</LINK>; <LINK REF="STD-Gignoux-1988" TYPE="STUDY">Gignoux 1988</LINK>; <LINK REF="STD-Launois-1981" TYPE="STUDY">Launois 1981</LINK>; <LINK REF="STD-Wang-1989" TYPE="STUDY">Wang 1989</LINK>) resectability did not appear to be substantially affected and a conventionally significant survival benefit was detected in only the most recent (<LINK REF="REF-Nygaard-1992" TYPE="REFERENCE">Nygaard 1992</LINK>). All but one of these trials involved fewer than 250 patients, and they were therefore, too small to detect moderate treatment effects. However, combining the results of these trials quantitatively in a meta-analysis of updated individual patient data, increases the statistical power to detect such differences and is the most reliable and unbiased way to evaluate the evidence (<LINK REF="REF-Parmar-1996" TYPE="REFERENCE">Parmar 1996</LINK>) from these trials.</P>
<P>Such a meta-analysis was therefore suggested by the Medical Research Council (MRC) Oesophageal Cancer Working Party, initiated by the MRC Cancer Trials Office, Cambridge, which became part of the MRC Clinical Trials Unit, and was carried out on behalf of the Oesophageal Cancer Collaborative Group (OCCG). Data was collated, checked and analysed by the MRC CTO. The collaborative group met in September 1995 to discuss the preliminary results. This review was first published by OCCG in the International Journal of Radiation Oncology Biology Physics (<LINK REF="REF-OCCG-1998" TYPE="REFERENCE">OCCG 1998</LINK>) and is reproduced with their permission.</P>
</BACKGROUND>
<OBJECTIVES>
<P>The existing randomized evidence has failed to conclusively demonstrate the benefit or otherwise of preoperative radiotherapy in treating patients with potentially resectable esophageal carcinoma. This meta-analysis aimed to assess whether there is benefit from adding radiotherapy prior to surgery. It also investigated whether any pre-defined patient subgroup would benefit more or less from preoperative radiotherapy.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-04-28 14:54:21 +0100" MODIFIED_BY="Cathy Bennett">
<SELECTION_CRITERIA>
<CRIT_STUDIES MODIFIED="2009-03-31 14:29:49 +0100" MODIFIED_BY="[Empty name]">
<P>Trials (published or unpublished) were eligible for inclusion in this meta-analysis provided they randomized patients with potentially resectable carcinoma of the esophagus (of any histological type) to receive radiotherapy or no radiotherapy prior to surgery. Trials must have used a randomization method, which precluded prior knowledge of the treatment assignment and completed accrual. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Individuals with potentially resectable carcinoma of the esophagus (of any histological type). Individual data from all randomized patients were included in the meta-analysis. Where possible data were obtained for individuals who had been excluded from the original trial analyses and they were included in the meta-analysis.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Trials that compared radiotherapy prior to surgery with surgery alone.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>Survival</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-04-28 14:54:21 +0100" MODIFIED_BY="Cathy Bennett">
<P>Trials were identified by computerized searching of MEDLINE and CANCERLIT, using a modification of the optimal search strategy for identifying randomized controlled trials developed by the Cochrane Collaboration (<LINK REF="REF-Dickersin-1995" TYPE="REFERENCE">Dickersin 1995</LINK>), and EMBASE and by examining the reference lists of trial publications, review articles, and books. Trial investigators collaborating in the meta-analysis and trial registers (United Kingdom Coordinating Committee on Cancer Research Register of Cancer Clinical Trials, Physicians Data Query Clinical Protocols and the Cochrane Controlled Trials Register) were also consulted to help identify unpublished and other published trials. The search strategy was run again in MEDLINE, EMBASE and the Cochrane Library on 30th April 2000; in MEDLINE, EMBASE, CancerLit and The Cochrane Library on August 2002 and August 2003; on MEDLINE, EMBASE and the Cochrane Library, on July 2004 and 2005, June 2006 and September 2008. No new relevant trials were identified on any of these occasions.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-03-31 14:30:14 +0100" MODIFIED_BY="[Empty name]">
<P>This review is based on individual patient data obtained directly from the responsible trialist or data centre. The methods used were prespecified in a protocol.</P>
<P>For all eligible trials, information on the following were requested: sex; date of birth or age; tumor location; disease stage; histology; extent of resection; date of randomization; allocated treatment; survival status and updated information on date of death or last follow up. Such information was sought also for patients who had been excluded from the investigators' own analysis, to prevent the potential bias of patient exclusions. No quality of life data were available. Following transfer, each trial dataset was checked thoroughly to ensure both the accuracy of the meta-analysis database and the quality of randomization and follow-up. Queries were resolved by, and the final database entries verified by, the responsible trial investigator or data manager.</P>
<P>The role of preoperative radiotherapy was investigated in four trials (<LINK REF="STD-Arnott-1992" TYPE="STUDY">Arnott 1992</LINK>; <LINK REF="STD-Gignoux-1988" TYPE="STUDY">Gignoux 1988</LINK>; <LINK REF="STD-Launois-1981" TYPE="STUDY">Launois 1981</LINK>; <LINK REF="STD-Wang-1989" TYPE="STUDY">Wang 1989</LINK>) and a fifth trial (<LINK REF="REF-Nygaard-1992" TYPE="REFERENCE">Nygaard 1992</LINK>) used a factorial design to examine the role of preoperative radiotherapy whilst controlling for the effect of chemotherapy. For this reason, the latter trial was split into two allowing separation of preoperative radiotherapy only 'trials' and preoperative radiotherapy plus chemotherapy 'trials' in the meta-analysis.</P>
<P>All analyses were carried out on an intention-to-treat basis. Survival analyses were stratified by trial and the logrank expected number of deaths and variance used to calculate individual and an overall pooled hazard ratio (HR) using the fixed effects model (<LINK REF="REF-Yusuf-1985" TYPE="REFERENCE">Yusuf 1985</LINK>). Thus the time to death for individual patients was used within trials to calculate HRs representing the overall risk of dying on treatment (preoperative radiotherapy) as compared to control (no preoperative radiotherapy). A simple (non-stratified) Kaplan-Meier curve was also generated (<LINK REF="REF-Kaplan-1958" TYPE="REFERENCE">Kaplan 1958</LINK>). Baseline survival at two and five years, as derived from the survival curve, together with the overall HR was used to calculate the absolute effect of treatment (<LINK REF="REF-Freedman-1982" TYPE="REFERENCE">Freedman 1982</LINK>). To investigate the effect of preoperative radiotherapy within pre-specified subgroups, similar stratified analyses were performed.</P>
<P>Chi square tests for heterogeneity were used to test for gross statistical heterogeneity over all trials (heterogeneity chi square) and between subgroups (interaction chi square). These tests are aimed primarily at detecting quantitative differences (differences in size rather than direction), because there was no a priori reason to expect qualitative differences. Where subgroups had a natural order (e.g. categories of increasing age) the chi square test for trend (trend chi square) was used.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-02-11 06:49:09 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2009-03-17 12:30:44 +0000" MODIFIED_BY="[Empty name]">
<P>At the time of analysis (1995), 8 potentially eligible trials were identified. Of these, 5 were eligible for inclusion in the meta-analysis. One was excluded, because it compared preoperative chemoradiotherapy plus surgery with surgery alone (<LINK REF="STD-Le-Prise-1994" TYPE="STUDY">Le Prise 1994</LINK>). The eligibility of two remaining trials (one published (<LINK REF="STD-Zhang-1988" TYPE="STUDY">Zhang 1988</LINK>) and one with no known publication details) could not be assessed fully and it was not clear that they were actually randomized controlled trials. It proved impossible to establish adequate communication with the trial investigators. Updated searches (to Sepetember 2008) did not uncover any new eligible trials, but rather two further trials comparing preoperative chemoradiotherapy plus surgery with surgery alone (<LINK REF="STD-de-Pree-1995" TYPE="STUDY">de Pree 1995</LINK>; <LINK REF="STD-Urba-1995" TYPE="STUDY">Urba 1995</LINK>).</P>
<P>The meta-analysis is based on five trials including 1147 patients (Table of included studies). This represents 98.5% of patients from all known randomised trials, because data were not available for 17 patients in one (<LINK REF="STD-Launois-1981" TYPE="STUDY">Launois 1981</LINK>) of the five trials. All trials included patients with potentially resectable cancer of the thoracic esophagus and with the exception of one (<LINK REF="STD-Arnott-1992" TYPE="STUDY">Arnott 1992</LINK>), restricted entry to patients with squamous carcinoma. Trials included both men and women of most age groups. In general, the majority of patients in the meta-analysis were men (78%), younger than 65 years (80%) with squamous carcinomas (86%) of the middle or lower third (74%) of the thoracic esophagus. The total planned dose of radiotherapy ranged from 20-40 Gy given in 10-20 fractions over a period of one to four weeks, with the delay from the end of radiotherapy to surgery ranging from less than eight days to four weeks. In all trials, the overall rates of resection and complete resection were broadly similar in the treatment and control arms.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-03-31 17:42:35 +0100" MODIFIED_BY="[Empty name]">
<P>Trials must have used a randomization method, which precluded prior knowledge of treatment assignment and completed accrual. Following transfer, each trial dataset was checked thoroughly to ensure both the accuracy of the meta-analysis database and the quality of randomisation and follow-up. Queries were resolved by, and the final database entries verified by, the responsible trial investigator or data manager.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-02-11 06:49:09 +0000" MODIFIED_BY="[Empty name]">
<P>The overall hazard ratio of 0.89, although not conventionally significant (chi square=3.48, df=1, p=0.06), suggests a moderate benefit from preoperative radiotherapy (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). It should be noted, however, that the meta-analysis had only about 75% power to detect such an effect. This effect represents an 11% reduction in the risk of death and an absolute benefit of 4% (95% CI 0 to 9%) at two years and 3% (95% CI 0 to 8%) at five years, improving survival from approximately 30 to 34% and 15 to 18% respectively (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). There was no evidence that this result varied when chemotherapy was used in conjunction with radiotherapy (interaction chi square=1.49, df=1, p=0.22), but there was some borderline evidence of a difference in effect across the trials (heterogeneity chi square=10.37, df=5, p=0.06). This seems to be mainly because of the extreme result of the Scandinavian trial (<LINK REF="REF-Nygaard-1992" TYPE="REFERENCE">Nygaard 1992</LINK>). Removing this trial reduces the overall heterogeneity (heterogeneity chi square=4.557, df=3, p=0.21), while keeping the results comparable (HR=0.96, p=0.53).</P>
<P>Pre-defined subgroups of patients were analysed to determine whether the size of the effect of preoperative radiotherapy varied across these groups. Only two trials had information on clinical staging and most patients (89%) had squamous carcinomas. Thus analyses by clinical stage and tumour histology were uninformative. Data on sex and age were available for at least 99% of patients, but on tumor location for only 80%, because one trial (<LINK REF="STD-Gignoux-1988" TYPE="STUDY">Gignoux 1988</LINK>) used a different method of classification. Based on these data, there was little evidence to suggest that any patient group, specified by sex (interaction chi square=3.15, df=1, p=0.08), age (trend chi square=0.76, df=1, p=0.38) or tumor location (interaction chi square=1.32, df=1, p=0.25), benefited more or less from preoperative radiotherapy (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-02-11 06:49:42 +0000" MODIFIED_BY="[Empty name]">
<P>This meta-analysis was based on five trials comparing preoperative radiotherapy with no preoperative radiotherapy. It included 1147 patients representing 98.5% of patients from all confirmed eligible randomized trials. Most of the survival data for these trials were updated for the meta-analysis, many years after the publication of the results and up to 20 years after recruitment had stopped. Therefore, currently, the meta-analysis provides the most comprehensive and reliable assessment of the effect of preoperative radiotherapy in potentially resectable esophageal cancer. Based on this existing evidence, there is a suggestion that preoperative radiotherapy may offer a modest benefit to patients, reducing the risk of death by 11% and improving absolute survival at two years, from 30 to 34% and at five years, from 15 to 18%. This effect was consistent irrespective of patient age and sex and the location of the tumour in the thoracic esophagus.</P>
<P>As a major aim of preoperative radiotherapy is to downstage the tumor and increase resectability, optimal results may rely on selecting appropriate patients. This will largely depend on accurate clinical staging. The rate of resection in the control arm varied between trials, which may suggest that clinical staging and so patient selection was also variable. Since these trials were performed, there have been two major changes in the staging of esophageal cancer, with international consensus (<LINK REF="REF-AJC-1988" TYPE="REFERENCE">AJC 1988</LINK>; <LINK REF="REF-UICC-1987" TYPE="REFERENCE">UICC 1987</LINK>). In addition, the advent of new diagnostic techniques, in particular endoscopic ultrasonography, seems to offer the potential for more accurate clinical staging (<LINK REF="REF-Thompson-1994" TYPE="REFERENCE">Thompson 1994</LINK>). It is possible, therefore, that with modern staging approaches, those patients most likely to benefit from preoperative treatment will be identified. Perhaps in these patients, any effect of preoperative radiotherapy on the rate of resection and survival will be easier to detect.</P>
<P>It is also possible that in these trials the radiotherapy dose was insufficient (particularly <LINK REF="STD-Arnott-1992" TYPE="STUDY">Arnott 1992</LINK>; <LINK REF="STD-Gignoux-1988" TYPE="STUDY">Gignoux 1988</LINK>; <LINK REF="REF-Nygaard-1992" TYPE="REFERENCE">Nygaard 1992</LINK>) or the delay between radiotherapy and surgery was too short to allow the inflammatory response to subside and tumor shrinkage to take place. Alternatively, it may have been that surgery was carried out too late, allowing fibrosis to occur. Indeed, based on a simple analysis, the expected improvement in resectability was not evident in these studies. If more detailed and informative analysis of the rates of resection become available in the future, the information will be incorporated into this review. Over time, the methods for administration of radiotherapy have changed and perhaps larger total doses to the tumor site or the same doses in a shorter time scale might be more effective.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-02-11 06:50:22 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2010-02-11 06:50:22 +0000" MODIFIED_BY="[Empty name]">
<P>This meta-analysis suggests that preoperative radiotherapy, as given in these trials, may provide a small survival advantage for patients with potentially resectable cancer of the esophagus and, moreover, there is no clear evidence to suggest that this therapy is detrimental, at least for survival. However, any small benefit of preoperative radiotherapy could be offset by the increased morbidity, cost, and duration of treatment associated with giving radiotherapy preoperatively. Therefore, preoperative radiotherapy cannot currently be routinely recommended outside of controlled clinical trials.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-04-28 13:44:10 +0100" MODIFIED_BY="[Empty name]">
<P>The subsequent research focus has been combined preoperative chemotherapy and preoperative radiotherapy and chemotherapy (<LINK REF="REF-Ajani-1995" TYPE="REFERENCE">Ajani 1995</LINK>), but this meta-analysis has failed to demonstrate conclusively that preoperative radiotherapy improves survival. Therefore, if more effective means of loco-regional control using preoperative radiotherapy with surgery can be found, the potential of additional systemic therapy could be assessed. Perhaps then trials of newer radiotherapy regimens followed by a longer (or shorter) delay to surgery, in carefully selected patients could reveal more substantial survival benefits. These would need to be considered alongside any changes in patient-reported quality of life. However, any such trials (or indeed a meta-analysis) would need to be substantially larger than those in the current meta-analysis. To reliably detect an absolute survival benefit of 5% would require 2000 patients and of 10% would require 600 patients (both 90% power, 5% significance). Such large trials would almost certainly necessitate large-scale international collaboration.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We would like to thank all those patients who took part in the trials and contributed to this research. The meta-analysis would not have been possible without their help or without the collaborating institutions who kindly supplied their trial data.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>There is no known conflict of interest.<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>All reviewers participated in the design, execution, and analysis of the review and twice commented on the overall intellectual content.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-02-11 07:13:44 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-02-11 07:07:44 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-02-11 07:07:44 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-Arnott-1992" MODIFIED="2010-02-11 07:04:06 +0000" MODIFIED_BY="[Empty name]" NAME="Arnott 1992" YEAR="1979">
<REFERENCE MODIFIED="2010-02-11 07:04:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arnott SJ, Duncan W, Kerr GR, Walbaum PR, Cameron E, Jack WJL et al</AU>
<TI>Low dose preoperative radiotherapy for carcinoma of the oesophagus: results of a randomized clinical trial</TI>
<SO>Radiotherapy and Oncology</SO>
<YR>1992</YR>
<VL>24</VL>
<PG>108-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Gignoux-1988" MODIFIED="2010-02-11 07:04:29 +0000" MODIFIED_BY="[Empty name]" NAME="Gignoux 1988" YEAR="1976">
<REFERENCE MODIFIED="2010-02-11 07:04:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gignoux M, Roussel A, Paillot B, Gillet M, Schlag P, Dalesio O et al</AU>
<TI>The value of preoperative radiotherapy in esophageal cancer: results of a study by the EORTC</TI>
<SO>Recent Results in Cancer Research</SO>
<YR>110</YR>
<VL>1988</VL>
<PG>1-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Launois-1981" MODIFIED="2010-02-11 06:56:56 +0000" MODIFIED_BY="[Empty name]" NAME="Launois 1981" YEAR="1973">
<REFERENCE MODIFIED="2010-02-11 06:56:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Launois B, Delarue D, Campion JP, Kerbaol M</AU>
<TI>Preoperative radiotherapy for carcinoma of the esophagus</TI>
<SO>Surgery, Gynecology and Obstetrics</SO>
<YR>1981</YR>
<VL>153</VL>
<PG>690-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Nygaard-1992-_x0028_a_x0029_" MODIFIED="2010-02-11 07:05:07 +0000" MODIFIED_BY="[Empty name]" NAME="Nygaard 1992 (a)" YEAR="1983">
<REFERENCE MODIFIED="2010-02-11 07:05:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nygaard K, Hagen S, Hansen HS, Hatlevoll R, Hultborn R, Jakobsen A, et al</AU>
<TI>Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer</TI>
<SO>World Journal of Surgery</SO>
<YR>1992</YR>
<VL>16</VL>
<PG>1104-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Nygaard-1992-_x0028_b_x0029_" MODIFIED="2010-02-11 07:07:44 +0000" MODIFIED_BY="[Empty name]" NAME="Nygaard 1992 (b)" YEAR="1983">
<REFERENCE MODIFIED="2010-02-11 07:07:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nygaard K, Hagen S, Hansen HS, Hatlevoll R, Hultborn R, Jakobsen A et al</AU>
<TI>Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer</TI>
<SO>World Journal of Surgery</SO>
<YR>1992</YR>
<VL>16</VL>
<PG>1104-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Wang-1989" MODIFIED="2010-02-11 06:58:59 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 1989" YEAR="1977">
<REFERENCE MODIFIED="2010-02-11 06:58:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang M, Gu XZ, Yin WB, Huang GJ, Wang LJ, Zhang DW</AU>
<TI>Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of esophageal carcinoma: report on 206 patients</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1989</YR>
<VL>16</VL>
<PG>325-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-02-11 07:03:41 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-de-Pree-1995" MODIFIED="2010-02-11 07:03:41 +0000" MODIFIED_BY="[Empty name]" NAME="de Pree 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-02-11 07:03:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Pree C, Aapro MS, Spiliopoulos A, Popowski Y, Mermillod B, Mirimanoff RO et al</AU>
<TI>Combined chemotherapy and radiotherapy, followed or not by surgery, in squamous cell carcinoma of the esophagus</TI>
<SO>Annals of Oncology</SO>
<YR>199</YR>
<VL>56</VL>
<NO>6</NO>
<PG>551-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Le-Prise-1994" MODIFIED="2010-02-11 07:03:22 +0000" MODIFIED_BY="[Empty name]" NAME="Le Prise 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-02-11 07:03:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Le Prise E, Etienne PL, Meunier B, Maddern G, Ben-Hassel M, Gedouin D et al</AU>
<TI>A randomized study of chemotherapy radiation therapy and surgery versus surgery for localized squamous call carcinoma of the esophagus</TI>
<SO>Cancer</SO>
<YR>1994</YR>
<VL>73</VL>
<NO>7</NO>
<PG>1779-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Urba-1995" MODIFIED="2010-02-11 07:02:58 +0000" MODIFIED_BY="[Empty name]" NAME="Urba 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-02-11 07:02:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Urba S, Orringer M, Turrisi A, Whyte R, Natale R, Iannettoni M et al</AU>
<TI>A randomized trial comparing transhiatial esophagectomy (THE) to preoperative concurrent chemoradiation (CT/XRT) followed by esophagectomy in locoregional esophageal carcinoma (CA)</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>1995</YR>
<VL>14</VL>
<PG>A475</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-1988" MODIFIED="2010-02-11 07:02:35 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-02-11 07:02:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang L, Xiqun D, Jiashun Y, Zhang W, Ping Y, Ma W et al</AU>
<TI>Treatment of the central section of the oesophagus using preoperative Cobalt60 radiation combined with surgery (comparative analysis of 200 cases)</TI>
<SO>Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>1988</YR>
<VL>4</VL>
<PG>31-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-02-11 07:13:44 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-02-11 07:13:06 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Ajani-1995" MODIFIED="2010-02-11 07:08:31 +0000" MODIFIED_BY="[Empty name]" NAME="Ajani 1995" TYPE="JOURNAL_ARTICLE">
<AU>Ajani J</AU>
<TI>A. Therapy of Carcinoma of the Oesophagus: Either Attempt it Not or Succeed</TI>
<SO>European Journal of Cancer</SO>
<YR>1995</YR>
<VL>31A</VL>
<PG>790-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-AJC-1988" MODIFIED="2009-04-28 13:51:16 +0100" MODIFIED_BY="[Empty name]" NAME="AJC 1988" TYPE="BOOK_SECTION">
<AU>American Joint Committee on Cancer</AU>
<SO>Manual for staging of cancer</SO>
<YR>1988</YR>
<PG>63-68</PG>
<EN>3rd</EN>
<ED>Beahrs OH, Henson DE, Hutter RV</ED>
<PB>JB Lippincott</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boring-1993" MODIFIED="2008-10-30 14:44:34 +0000" MODIFIED_BY="Karen Hovhannisyan" NAME="Boring 1993" TYPE="JOURNAL_ARTICLE">
<AU>Boring CC, Squires TS, Tong T</AU>
<TI>Cancer statistics</TI>
<SO>CA- Cancer J Clinicians</SO>
<YR>1993</YR>
<VL>43</VL>
<PG>7-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DeMeester-1988" MODIFIED="2010-02-11 07:09:30 +0000" MODIFIED_BY="[Empty name]" NAME="DeMeester 1988" TYPE="JOURNAL_ARTICLE">
<AU>DeMeester TR, Barlow A P</AU>
<TI>Surgery and current management for cancer of the esophagus and cardia</TI>
<SO>Current Problems in Cancer</SO>
<YR>1988</YR>
<VL>12</VL>
<PG>243-328</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1995" MODIFIED="2010-02-11 07:09:59 +0000" MODIFIED_BY="[Empty name]" NAME="Dickersin 1995" TYPE="BOOK_SECTION">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>Systematic Reviews</SO>
<YR>1995</YR>
<PG>17-36</PG>
<ED>Chalmers I, Altman DG</ED>
<PB>BMJ Publishing</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Freedman-1982" MODIFIED="2010-02-11 07:10:20 +0000" MODIFIED_BY="[Empty name]" NAME="Freedman 1982" TYPE="JOURNAL_ARTICLE">
<AU>Freedman LS</AU>
<TI>Tables of the number of patients required in clinical trials using the logrank test</TI>
<SO>Statistics in Medicine</SO>
<YR>1982</YR>
<VL>1</VL>
<PG>121-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kaplan-1958" MODIFIED="2008-10-30 14:44:34 +0000" MODIFIED_BY="Karen Hovhannisyan" NAME="Kaplan 1958" TYPE="JOURNAL_ARTICLE">
<AU>Kaplan EL, Meier P</AU>
<TI>Nonparametric estimation from incomplete observation</TI>
<SO>JAMA</SO>
<YR>1958</YR>
<VL>53</VL>
<PG>457-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nygaard-1992" MODIFIED="2010-02-11 07:11:16 +0000" MODIFIED_BY="[Empty name]" NAME="Nygaard 1992" TYPE="JOURNAL_ARTICLE">
<AU>Nygaard K, Hagen S, Hansen HS, Hatlevoll R, Hultborn R, Jakobsen A et al</AU>
<TI>Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer</TI>
<SO>World Journal of Surgery</SO>
<YR>1992</YR>
<VL>16</VL>
<PG>1104-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parmar-1996" MODIFIED="2010-02-11 07:11:40 +0000" MODIFIED_BY="[Empty name]" NAME="Parmar 1996" TYPE="JOURNAL_ARTICLE">
<AU>Parmar MKB, Stewart LS, Altman DG</AU>
<TI>Meta-analyses of randomised trials. When the whole is more than the just the sum of the parts</TI>
<SO>British Journal of Cancer</SO>
<YR>1996</YR>
<VL>74</VL>
<PG>496-501</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thompson-1994" MODIFIED="2010-02-11 07:12:09 +0000" MODIFIED_BY="[Empty name]" NAME="Thompson 1994" TYPE="JOURNAL_ARTICLE">
<AU>Thompson WM, Halvorsen RA, Jr</AU>
<TI>Staging Esophageal Carcinoma II: CT and MRI</TI>
<SO>Seminars in Oncology</SO>
<YR>1994</YR>
<VL>21</VL>
<PG>447-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-UICC-1987" MODIFIED="2008-10-30 14:44:34 +0000" MODIFIED_BY="Karen Hovhannisyan" NAME="UICC 1987" TYPE="BOOK_SECTION">
<AU>Union Internationale Contre le Cancer</AU>
<SO>TNM classification of malignant tumours</SO>
<YR>1987</YR>
<PG>80-89</PG>
<EN>4th</EN>
<ED>Hermanek P, Sobin LH</ED>
<PB>Springer-Verlag</PB>
<CY>Berlin</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yusuf-1985" MODIFIED="2010-02-11 07:13:06 +0000" MODIFIED_BY="[Empty name]" NAME="Yusuf 1985" TYPE="JOURNAL_ARTICLE">
<AU>Yusuf S, Peto R, Lewis J, Collins R, Sleight P</AU>
<TI>Beta blockade during and after myocardial infarction: an overview of randomised clinical trials</TI>
<SO>Progress in Cardiovascular Diseases</SO>
<YR>1985</YR>
<VL>27</VL>
<PG>335-71</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2010-02-11 07:13:44 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-OCCG-1998" MODIFIED="2010-02-11 07:13:44 +0000" MODIFIED_BY="[Empty name]" NAME="OCCG 1998" TYPE="JOURNAL_ARTICLE">
<AU>Arnott SJ, Duncan W, Gignoux M, Girling DJ, Hansen HS, Launois B et al</AU>
<TI>Preoperative radiotherapy in esophageal carcinoma: a meta-analysis using individual patient data (Oesophageal Cancer Collaborative Group)</TI>
<SO>International Journal of Radiation Oncology Biology Physics</SO>
<YR>1998</YR>
<VL>41</VL>
<NO>3</NO>
<PG>579-83</PG>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-03-17 12:58:22 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-03-17 12:58:22 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Arnott-1992">
<CHAR_METHODS>
<P>RCT, 1979-1983</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>176 patients with potentially resectable squamous cell or adenocarcinoma</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Surgery with or without prior radiotherapy*<BR/>*20Gy in 10 fractions over 14 days. 21 days delay to surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>84% resections, 76% complete resections on treatment<BR/>75% resections, 72% complete resections on control</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gignoux-1988">
<CHAR_METHODS>
<P>RCT, 1976-1982</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>229 patients with potentially resectable squamous cell carcinoma</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Surgery with or without prior radiotherapy*<BR/>*33Gy in 10 fractions over 28 days. &lt;8 days delay to surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>68% resections, 43% complete resections on treatment<BR/>78% resections, 55% complete resections on control</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Launois-1981">
<CHAR_METHODS>
<P>RCT, 1973-1976</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>107 patients with potentially resectable squamous cell carcinoma</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Surgery with or without prior radiotherapy*<BR/>*40Gy in ? fractions over 8-12 days. &lt;8 days delay to surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>89% resections, 74% complete resections on treatment<BR/>89% resections, 78% complete resections on control</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Nygaard-1992-_x0028_a_x0029_">
<CHAR_METHODS>
<P>RCT, 1983-1988</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>108 patient with potentially resectable squamous cell carcinoma</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Surgery with or without prior radiotherapy*<BR/>*35Gy in 20 fractions over 28 days. 21 days delay to surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>46% resections, 34% complete resections on treatment<BR/>62% resections, 32% complete resections on control</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Nygaard-1992-_x0028_b_x0029_">
<CHAR_METHODS>
<P>RCT, 1983-1988</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>109 patients with potentiall resectable squamous cell carcinoma</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Surgery with or without prior chemotherapy and radiotherapy*<BR/>*35Gy in 20 fractions over 28 days. 21 days delay to surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>62% resections, 53% complete resections on treatment<BR/>55% resections, 41% complete resections on control</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wang-1989">
<CHAR_METHODS>
<P>RCT, 1977-1988</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>418 patients with potentially resectable squamous cell carcinoma</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Surgery with or without radiotherapy*<BR/>*40Gy in 10 fractions over 12 day. 14-28 days delay to surgery<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>90% resections, 74% complete resections on treatment<BR/>86% resections, 65% complete resections on control</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-de-Pree-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Compared preoperative chemoradiotherapy plus surgery with surgery alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Le-Prise-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Compared preoperative chemoradiotherapy plus surgery with surgery alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Urba-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Compared preoperative chemoradiotherapy plus surgery with surgery alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zhang-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Eligibility uncertain:<BR/>Unsure that it was RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-03-17 12:58:22 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-03-17 12:58:22 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Arnott-1992">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Gignoux-1988">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Launois-1981">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Nygaard-1992-_x0028_a_x0029_">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Nygaard-1992-_x0028_b_x0029_">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Wang-1989">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-03-31 13:29:26 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2009-03-31 13:28:47 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Preoperative radiotherapy (with or without chemotherapy) versus (with or without chemotherapy) surgery</NAME>
<IPD_OUTCOME CHI2="10.204901715553163" CI_END="1.0072548112847246" CI_START="0.7828931158891059" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_SIZE="0.8880162485568558" ESTIMABLE="YES" EVENTS_1="480" EVENTS_2="491" I2="51.00393772161898" I2_Q="33.971074764638644" ID="CMP-001.01" LOG_CI_END="0.003139350529927772" LOG_CI_START="-0.10629752574294864" LOG_EFFECT_SIZE="-0.051579087606510414" MODIFIED="2009-03-31 13:28:47 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.06963336753097527" P_Q="0.21845596853906502" P_Z="0.06467248636415397" Q="1.5144877740103766" SCALE="10.0" SORT_BY="USER" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="573" TOTAL_2="574" WEIGHT="100.00000000000001" Z="1.847515344135465">
<NAME>Survival</NAME>
<GROUP_LABEL_1>Preoperative RT</GROUP_LABEL_1>
<GROUP_LABEL_2>No Preoperative RT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Preop RT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours No Preop RT</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="8.690413941542786" CI_END="1.0409582246415832" CI_START="0.7982810286340736" DF="4" EFFECT_SIZE="0.911579509605159" ESTIMABLE="YES" EVENTS_1="434" EVENTS_2="438" I2="53.97227304813641" ID="CMP-001.01.01" LOG_CI_END="0.017433300911414748" LOG_CI_START="-0.0978441917328798" LOG_EFFECT_SIZE="-0.040205445410732496" NO="1" P_CHI2="0.06932108597408249" P_Z="0.17157604860039444" STUDIES="5" TAU2="0.0" TOTAL_1="520" TOTAL_2="518" WEIGHT="90.12355882474483" Z="1.3671571645052958">
<NAME>Preoperative RT only 'trials'</NAME>
<IPD_DATA CI_END="1.5250329799752884" CI_START="0.6686149069414736" EFFECT_SIZE="1.0097820477651878" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="40" LOG_CI_END="0.18327923572635016" LOG_CI_START="-0.17482394492823378" LOG_EFFECT_SIZE="0.004227645399058248" ORDER="1" O_E="0.22" SE="0.21035158095583562" STUDY_ID="STD-Launois-1981" TOTAL_1="61" TOTAL_2="46" VAR="22.6" WEIGHT="9.339228893755942"/>
<IPD_DATA CI_END="1.3316234637183593" CI_START="0.7800290130948149" EFFECT_SIZE="1.019168747665533" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="108" LOG_CI_END="0.12438143898810719" LOG_CI_START="-0.10788924347279384" LOG_EFFECT_SIZE="0.008246097757656645" ORDER="2" O_E="1.02" SE="0.13643694863595454" STUDY_ID="STD-Gignoux-1988" TOTAL_1="116" TOTAL_2="113" VAR="53.72" WEIGHT="22.199264432414566"/>
<IPD_DATA CI_END="1.0093263274778073" CI_START="0.6490675162517194" EFFECT_SIZE="0.8093954116891756" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="165" LOG_CI_END="0.004031601628562108" LOG_CI_START="-0.18771012537148257" LOG_EFFECT_SIZE="-0.0918392618714602" ORDER="3" O_E="-16.67" SE="0.11263003957668236" STUDY_ID="STD-Wang-1989" TOTAL_1="195" TOTAL_2="223" VAR="78.83" WEIGHT="32.575726269680565"/>
<IPD_DATA CI_END="1.6164540035257913" CI_START="0.8698754154583024" EFFECT_SIZE="1.1857966089874916" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="75" LOG_CI_END="0.2085633511998832" LOG_CI_START="-0.060542943074936864" LOG_EFFECT_SIZE="0.0740102040624732" ORDER="4" O_E="6.82" SE="0.15807436935466976" STUDY_ID="STD-Arnott-1992" TOTAL_1="90" TOTAL_2="86" VAR="40.02" WEIGHT="16.5378734658457"/>
<IPD_DATA CI_END="0.908607336072325" CI_START="0.4006652643423994" EFFECT_SIZE="0.603363404998067" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="50" LOG_CI_END="-0.041623761024730116" LOG_CI_START="-0.39721830707646144" LOG_EFFECT_SIZE="-0.2194210340505958" ORDER="5" O_E="-11.58" SE="0.20887799657217843" STUDY_ID="STD-Nygaard-1992-_x0028_a_x0029_" TOTAL_1="58" TOTAL_2="50" VAR="22.92" WEIGHT="9.471465763048062"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.0" CI_END="1.0441169378308373" CI_START="0.4682969554230803" DF="0" EFFECT_SIZE="0.6992544480315093" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="53" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.01874914101360557" LOG_CI_START="-0.32947866572262674" LOG_EFFECT_SIZE="-0.1553647623545106" NO="2" P_CHI2="1.0" P_Z="0.08030678433382983" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="56" WEIGHT="9.876441175255177" Z="1.7489088050462214">
<NAME>Preoperative RT + CT 'trials'</NAME>
<IPD_DATA CI_END="1.0441169378308373" CI_START="0.4682969554230803" EFFECT_SIZE="0.6992544480315093" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="53" LOG_CI_END="0.01874914101360557" LOG_CI_START="-0.32947866572262674" LOG_EFFECT_SIZE="-0.1553647623545106" ORDER="1" O_E="-8.55" SE="0.20455073743230656" STUDY_ID="STD-Nygaard-1992-_x0028_b_x0029_" TOTAL_1="53" TOTAL_2="56" VAR="23.9" WEIGHT="9.876441175255177"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-03-31 13:29:19 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2009-03-31 13:29:19 +0100" MODIFIED_BY="[Empty name]" NO="1" REF_ID="CMP-001.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Preoperative radiotherapy (with or without chemotherapy) versus (with or without chemotherapy) surgery, outcome: 1.1 Survival.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA6sAAAGQCAMAAAB/HgbwAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="KM curve.jpg" FILE_TYPE="JPG" ID="FIG-02" MODIFIED="2009-03-26 18:53:16 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Simple (non-stratified) survival curves of preoperative radiotherapy (with or without chemotherapy) versus (with or without chemotherapy) surgery.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="subgroup HRs.jpg" FILE_TYPE="JPG" ID="FIG-03" MODIFIED="2009-03-26 18:53:10 +0000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Effect of preoperative radiotherapy (with or without chemotherapy) versus (with or without chemotherapy) surgery by sex, age and tumor location. Sex: interaction chisquare=3.15, df=1, p=0.08; Age: Sex: trend chisquare=0.76, df=1, p=0.38; tumor location: intercation chisquare= 1.31, df=1, p=0.25.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2009-04-28 14:53:55 +0100" MODIFIED_BY="Cathy Bennett">
<APPENDIX ID="APP-01" MODIFIED="2009-04-28 14:53:55 +0100" MODIFIED_BY="Cathy Bennett" NO="1">
<TITLE MODIFIED="2009-04-28 14:53:52 +0100" MODIFIED_BY="Cathy Bennett">Search Strategy for MEDLINE and CANCERLIT (modified for Probase software)</TITLE>
<APPENDIX_BODY MODIFIED="2009-04-28 14:53:55 +0100" MODIFIED_BY="Cathy Bennett">
<P>1 PT=RANDOMIZED-CONTROLLED-TRIAL<BR/>2 RANDOMIZED-CONTROLLED-TRIALS.DE<BR/>3 RANDOM-ALLOCATION.DE<BR/>4 DOUBLE-BLIND-METHOD.DE.<BR/>5 SINGLE-BLIND-METHOD.DE.<BR/>6 1 OR 2 OR 3 OR 4 OR 5<BR/>7 PT=CLINICAL-TRIAL<BR/>8 CLINICAL-TRIALS#.DE.<BR/>9 CLIN$ WITH TRIAL$).AB,TI.<BR/>10 ((SINGL$ OR DOUBL$ OR TREBL$ OR TRIPL$) WITH (BLIND$ OR MASK$)).AB,TI.<BR/>11 PLACEBO$.DE.<BR/>12 PLACEBO$.AB,TI.<BR/>13 RANDOM$.AB,TI.<BR/>14 RESEARCH-DESIGN.DE.<BR/>15 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14<BR/>16 CARCINOMA#.DE.<BR/>17 ESOPHAGEAL-NEOPLASMS.DE.<BR/>18 16 and 17<BR/>19 (ESOPHAG$ ADJ CARCINOMA$).AB,TI.<BR/>20 (ESOPHAG$ ADJ CANCER$).AB,TI.<BR/>21 (ESOPHAG$ ADJ NEOPLASM$).AB,TI.<BR/>22 (OESOPHAG$ ADJ CARCIMOMA$).AB,TI.<BR/>23 (OESOPHAG$ ADJ CANCER$).AB,TI.<BR/>24 (OESOPHAG$ ADJ NEOPLASM$).AB,TI.<BR/>25 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24<BR/>26 Radiotherapy.DE.<BR/>27 QS Neoplasms WITH RT<BR/>28 26 or 27<BR/>29 15 and 25 and 28</P>
<P>Please note: Format shown is for Knight-Ridder Probase version 1.1<BR/>$ is a truncation symbol<BR/># denotes an exploded term</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>